237,995 Shares in BridgeBio Pharma, Inc. (NASDAQ:BBIO) Bought by Susquehanna Fundamental Investments LLC

Susquehanna Fundamental Investments LLC bought a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 237,995 shares of the company's stock, valued at approximately $6,531,000. Susquehanna Fundamental Investments LLC owned approximately 0.13% of BridgeBio Pharma as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of BBIO. Steward Partners Investment Advisory LLC raised its position in BridgeBio Pharma by 85.8% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares in the last quarter. Sterling Capital Management LLC raised its holdings in shares of BridgeBio Pharma by 554.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after buying an additional 1,514 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of BridgeBio Pharma in the 4th quarter worth approximately $181,000. First Bank & Trust acquired a new stake in BridgeBio Pharma in the 4th quarter valued at $205,000. Finally, Moss Adams Wealth Advisors LLC bought a new stake in BridgeBio Pharma in the fourth quarter valued at $208,000. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Price Performance

BBIO traded up $0.17 during trading on Friday, reaching $38.57. The company had a trading volume of 3,168,027 shares, compared to its average volume of 2,352,389. The company has a market cap of $7.32 billion, a P/E ratio of -13.53 and a beta of 1.08. BridgeBio Pharma, Inc. has a 12 month low of $21.62 and a 12 month high of $39.54. The business's fifty day moving average price is $34.06 and its 200 day moving average price is $30.88.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.12. The company had revenue of $36.74 million during the quarter, compared to the consensus estimate of $57.14 million. The company's revenue was down 44.8% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.20) earnings per share. As a group, sell-side analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a report on Monday, March 24th. Citigroup upped their price objective on shares of BridgeBio Pharma from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. HC Wainwright lifted their target price on shares of BridgeBio Pharma from $49.00 to $53.00 and gave the company a "buy" rating in a research note on Tuesday, April 15th. Redburn Atlantic initiated coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 price target on the stock. Finally, Piper Sandler increased their target price on BridgeBio Pharma from $46.00 to $63.00 and gave the stock an "overweight" rating in a report on Wednesday. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $57.09.

Insider Activity

In other BridgeBio Pharma news, Director Andrea Ellis sold 30,000 shares of the business's stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $34.05, for a total value of $1,021,500.00. Following the sale, the director now owns 12,000 shares in the company, valued at approximately $408,600. The trade was a 71.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Neil Kumar sold 75,000 shares of the firm's stock in a transaction on Tuesday, April 22nd. The shares were sold at an average price of $34.11, for a total transaction of $2,558,250.00. Following the completion of the transaction, the chief executive officer now directly owns 4,873,447 shares of the company's stock, valued at approximately $166,233,277.17. This trade represents a 1.52 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 6,309,191 shares of company stock worth $208,544,821 over the last three months. Corporate insiders own 24.66% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.